Compare Stocks: VOR, GRFS, ACAD, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$30.57 +3.1%	$26.32	$19.69 ▼ $30.96	$5.11B	0.81	1.81 million shs	1.52 million shs
DYN Dyne Therapeutics	$26.34 +1.3%	$23.99	$11.92 ▼ $27.31	$4.85B	1.07	1.88 million shs	1.46 million shs
GRFS Grifols	$8.09 +1.3%	$7.61	$6.96 ▼ $10.23	$5.44B	0.66	532,175 shs	375,056 shs
VOR Vor Biopharma	$24.01 +5.7%	$19.89	$6.50 ▼ $49.95	$1.34B	1.73	786,345 shs	1.22 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+3.10%	+1.29%	+23.07%	+44.27%	+20.73%
DYN Dyne Therapeutics	+1.35%	+1.31%	+7.77%	+45.04%	+102.62%
GRFS Grifols	+1.25%	+4.39%	+6.73%	+0.50%	-17.62%
VOR Vor Biopharma	+5.72%	+3.14%	+24.66%	+54.70%	-41.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$30.57 +3.1%	$26.32	$19.69 ▼ $30.96	$5.11B	0.81	1.81 million shs	1.52 million shs
DYN Dyne Therapeutics	$26.34 +1.3%	$23.99	$11.92 ▼ $27.31	$4.85B	1.07	1.88 million shs	1.46 million shs
GRFS Grifols	$8.09 +1.3%	$7.61	$6.96 ▼ $10.23	$5.44B	0.66	532,175 shs	375,056 shs
VOR Vor Biopharma	$24.01 +5.7%	$19.89	$6.50 ▼ $49.95	$1.34B	1.73	786,345 shs	1.22 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+3.10%	+1.29%	+23.07%	+44.27%	+20.73%
DYN Dyne Therapeutics	+1.35%	+1.31%	+7.77%	+45.04%	+102.62%
GRFS Grifols	+1.25%	+4.39%	+6.73%	+0.50%	-17.62%
VOR Vor Biopharma	+5.72%	+3.14%	+24.66%	+54.70%	-41.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	12.40% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	30.66% Upside
GRFS Grifols	1.67	Reduce	$10.00	23.61% Upside
VOR Vor Biopharma	2.82	Moderate Buy	$43.38	80.65% Upside

Current Analyst Ratings Breakdown

Latest VOR, GRFS, ACAD, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/17/2026	GRFS Grifols	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/17/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/12/2026	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $27.00
8/11/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.92	$0.91 per share	33.42	$7.58 per share	4.03
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$3.76 per share	N/A
GRFS Grifols	$7.42B	0.74	$1.43 per share	5.64	$13.63 per share	0.59
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.77	31.19	23.35	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	42.58	6.18	0.29	5.54%	6.21%	2.39%	11/10/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VOR, GRFS, ACAD, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.09	1.11%	N/A	47.37%	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Latest VOR, GRFS, ACAD, and DYN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2026	GRFS Grifols	special	$0.0945		7/2/2026	7/2/2026	7/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
DYN Dyne Therapeutics	0.28	12.02	12.02
GRFS Grifols	1.10	2.37	0.81
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
DYN Dyne Therapeutics	96.68%
GRFS Grifols	N/A
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
DYN Dyne Therapeutics	9.46%
GRFS Grifols	0.19%
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
VOR Vor Biopharma	140	59.16 million	59.00 million	N/A

VOR, GRFS, ACAD, and DYN Headlines

Recent News About These Companies

FY2030 EPS Estimates for Vor Biopharma Lowered by Analyst

August 15, 2026 | americanbankingnews.com

Vor Biopharma (NASDAQ:VOR) Rating Increased to Hold at Wall Street Zen

August 15, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

August 15, 2026 | marketbeat.com

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 14, 2026 | marketbeat.com

Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright

August 13, 2026 | marketbeat.com

Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

August 12, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings

August 12, 2026 | marketbeat.com

Vor Biopharma Shares Drop After Q2 Results

August 11, 2026 | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Posts Earnings Results

August 11, 2026 | marketbeat.com

Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | finanznachrichten.de

Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR

August 11, 2026 | marketbeat.com

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts

August 9, 2026 | marketbeat.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors

July 8, 2026 | finanznachrichten.de

Vor Bio Appoints David Zaccardelli to Board of Directors

July 7, 2026 | globenewswire.com

Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes

July 7, 2026 | seekingalpha.com

Vor Biopharma Stock Short Interest Report | NASDAQ:VOR | Benzinga

July 3, 2026 | benzinga.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next

June 30, 2026 | finance.yahoo.com

Vor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

June 8, 2026 | finanznachrichten.de

Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China

June 8, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VOR, GRFS, ACAD, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$30.57 +0.92 (+3.10%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$30.92 +0.34 (+1.13%)

As of 08/25/2026 05:43 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Dyne Therapeutics NASDAQ:DYN

$26.34 +0.35 (+1.35%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$26.34 0.00 (-0.02%)

As of 08/25/2026 04:15 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Grifols NASDAQ:GRFS

$8.09 +0.10 (+1.25%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$8.09 0.00 (0.00%)

As of 08/25/2026 04:10 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Vor Biopharma NASDAQ:VOR

$24.01 +1.30 (+5.72%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$23.99 -0.02 (-0.08%)

As of 08/25/2026 04:20 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VOR, GRFS, ACAD, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VOR, GRFS, ACAD, and DYN Earnings

Compare Dividends

Latest VOR, GRFS, ACAD, and DYN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VOR, GRFS, ACAD, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VOR, GRFS, ACAD, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Dyne Therapeutics NASDAQ:DYN

Grifols NASDAQ:GRFS

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools